Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Cardiovascular Agent Market Increases 2.6% to 1.363 Billion Yen in 2011: Fuji-Keizai
May 30, 2012
- Takeda to Acquire Multilab of Brazil to Boost Business Infrastructure through OTC Drugs
May 29, 2012
- CMIC Subsidiary to Expand Non-Clinical Operations by Business Transfer
May 29, 2012
- Chugai Files NDA for Breast Cancer Treatment Pertuzumab in Japan
May 29, 2012
- Sanofi-aventis Applies for Switch OTC Allegra, PAFSC Committee to Review on June 7
May 28, 2012
- 26 TSE 1st-Section Drug Makers Post Overall Decline in Sales, Profits for FY2011: JPMA
May 28, 2012
- Meiji Seika Pharma Aims to Increase No. of MRs to 900 as Soon as Possible
May 28, 2012
- Nearly 30% Use “Only Neostigmine”: Neuromuscular Antagonists Usage Survey
May 28, 2012
- US Subsidiary of DSP Settles COPD Drug Patent Infringement Suit
May 28, 2012
- DPP-4 Inhibitors Gain Traction, Boosting Diabetes Market by 15.5%: IMS Japan
May 25, 2012
- Zeria Projects 19% Increase in Asacol Sales to 12.2 Billion Yen in FY2012
May 25, 2012
- Japanese Ethical Drug Market Expands by 5.5% to 9.5348 Trillion Yen: IMS Japan
May 25, 2012
- Takeda Files MAA for Alogliptin in Europe
May 25, 2012
- National Cancer Center, Daiichi Sankyo Conclude Comprehensive Joint Research Agreement for Cancer Drug Discovery
May 24, 2012
- RIKEN and Takeda Open Collaboration Center for Developing Drug Discovery Technology for CNS Diseases
May 24, 2012
- Daiichi Sankyo Completes Patient Recruitment in Overseas PIII Trial of ARQ 197 for NSCLC
May 24, 2012
- Xarelto No. 1, Prazaxa Ranks 2nd in Call Frequency in HP Market: Rep Track April Survey
May 24, 2012
- Meiji HD Targets Pharmaceuticals Segment Sales at 140 Billion Yen in FY2014
May 23, 2012
- Four Major Listed Dispensing Pharmacies Post Record Performance in FY2011
May 23, 2012
- Myslee Is Most Prescribed Insomnia Drug: Survey
May 23, 2012
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…